Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

What Is the potential value of MANF to treat Alzheimer's?

Although there have been three medicines approved for Alzheimer's disease since 2000, there is still a substantial unmet medical need, including for disease modifying therapy. Existing drugs offer some benefits to some patients but they treat the symptoms only. Alzheimer’s disease is one of the largest and fastest growing diseases in the U.S., both in terms of human suffering and costs to the health care system.

Over 5 million Americans, or one in eight people age 65 or over and almost half of individuals age 85 or over, were estimated to have Alzheimer’s disease in 2012. By 2050, the number of Americans with Alzheimer’s disease is expected to triple without advances that would prevent, slow, or stop disease progression. Without such improvements, direct costs are expected to increase from approximately $170 billion in 2012 to over a trillion dollars in 2050.

A medicine that could delay the onset of the disease was estimated to reduce the cost of care of Alzheimer’s patients in 2050 to all payers by $447 billion.

Note: The F.D.A. granting O.D.D. for MANF for Retinitis Pigmentosa will be a major step forward for MANF for numerous indications.